FDA Approves Olaparib, a PARP Inhibitor, for BRCA+ Breast Cancer


FDA Approves Olaparib, a PARP Inhibitor, for BRCA+ Breast Cancer

With the decision aid, half of the women scored at least 80 out of 100 on tests of their knowledge about breast cancer and treatment options, compared with a median score of 66 for women who reviewed material on various websites. The mutations put women at greater risk of breast and ovarian cancers, with 45 to 90 per cent of women with the mutation developing breast cancer during their lifetime.

Having a faulty BRCA gene - either BRCA1 or BRCA2 - is known to increase a woman's risk of breast cancer.

"There is actually plenty of time to review all treatment options since survival rates are very high for early-stage breast cancer and do not change if a woman starts treatment within a few weeks", Mitchell said by email. At that time, BRCA testing and risk-reducing surgery were not routine for early breast cancer.

This is the finding of a prospective cohort study led by the University of Southampton, UK.

FRIDAY, Jan. 12, 2018 (HealthDay News) - Survival appears to be similar for patients with young-onset breast cancer who carry a BRCA mutation and noncarriers, according to a study published online Jan. 11 in The Lancet Oncology. AstraZeneca and Merck are working together to deliver Lynparza as quickly as possible to more patients across multiple settings, including breast, ovarian, prostate, and pancreatic cancers. Actually, those with a BRCA mutation had slightly higher survival rates for the first two years after diagnosis, in the case of patients with triple-negative breast cancer.

Young women with the BRCA gene mutation that prompted actress Angelina Jolie's pre-emptive and much-publicised double mastectomy are not more likely to die after a breast cancer diagnosis, scientists said Friday.

BRCA mutations interfere with DNA fix, making carriers predisposed to develop cancer.

AstraZeneca said this is the third indication approved for Lynparza in the USA, where it has been used to treat almost 4,000 advanced ovarian cancer patients.

Some women have previously chose to take preventative measures, such as pre-emptive mastectomies, when they discover they have faulty genes.

The team tracked the women's medical records for an average period of just over eight years and found that 651 of 678 total deaths were due to breast cancer.

Angelina Jolie made headlines when she underwent preventative surgery after learning she had an up to 87% chance of developing breast cancer.

'However, our findings suggest that this surgery does not have to be immediately undertaken along with the other treatment. There was no significant difference in overall survival between patients who were BRCA positive and those who were BRCA negative at 2 years (97% vs 96.6%, respectively), 5 years (83.8% vs 85%), or 10 years (73.4% vs 70.1%; hazard ratio, 0.96; 95% CI, 0.76-1.22; P = 0.76).

Surgery may still be beneficial for patients to reduce their risk in the longer term, such as two to three decades after their initial diagnosis, she said.

"Decisions about timing of additional surgery aimed at reducing future second primary-cancer risks should take into account patient prognosis associated with the first malignancy and patient preferences", the authors write.